N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: Randomized, placebo-controlled pilot study

Table 2 Changes in disease activity assessed using modified Truelove-Witts Severity Index (mean ± SD) in subjects who received the drugs for 2 wk and 4 wk

Week of treatment	0	2	4	ANOVA statistical test (number of patients)
Group A mesalamine plus NAC	5.95 ± 2.22	4.68 ± 3.40	3.32 ± 3.71a	P = 0.046 (n = 19)
Group B mesalamine plus placebo	4.61 ± 2.09	4.17 ± 3.85	3.72 ± 3.91	P = 0.735 (n = 18)

^aP < 0.05 represents the significance levels compared with the corresponding basal values using the ANOVA statistical test.